Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications

Abstract

Context: Prostate-specific membrane antigen (PSMA) is a promising, novel theranostic target in advanced prostate cancer (PCa). Multiple PSMA-targeted therapies are currently in clinical development, with some agents showing impressive antitumour activity, although optimal patient selection and therapeutic resistance remain ongoing challenges. Objective: To review the biology of PSMA and recent advances in PSMA-targeted therapies in PCa, and to discuss potential strategies for patient selection and further therapeutic development. Evidence acquisition: A comprehensive literature search was performed using PubMed and review of American Society of Clinical Oncology and European Society of Medical Oncology annual meeting abstracts up to April 2021. Evidence synthesis: PSMA is a largely extracellular protein that is frequently, but heterogeneously, expressed by PCa cells. PSMA expression is associated with disease progression, worse clinical outcomes and the presence of tumour defects in DNA damage repair (DDR). PSMA is also expressed by other cancer cell types and is implicated in glutamate and folate metabolism. It may confer a tumour survival advantage in conditions of cellular stress. PSMA regulation is complex, and recent studies have shed light on interactions with androgen receptor, PI3K/Akt, and DDR signalling. A phase 2 clinical trial has shown that 177 Lu-PSMA-617 causes tumour shrinkage and delays disease progression in a significant subset of patients with metastatic castration-resistant PCa in comparison to second-line chemotherapy. Numerous novel PSMA-targeting immunotherapies, small molecules, and antibody therapies are currently in clinical development, including in earlier stages of PCa, with emerging evidence of antitumour activity. To date, the regulation and function of PSMA in PCa cells remain poorly understood. Conclusions: There has been rapid recent progress in PSMA-targeted therapies for the management of advanced PCa. Dissection of PSMA biology will help to identify biomarkers for and resistance mechanisms to these therapies and facilitate further therapeutic development to improve PCa patient outcomes. Patient summary: There have been major advances in the development of therapies targeting a molecule, PSMA, in PCa. Radioactive molecules targeting PSMA can cause tumour shrinkage and delay progression in some patients with lethal disease. Future

18F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

“…PSMA is a protein overexpressed in PCa tumor cells, and this is the rationale for using PSMA-targeted agents in the diagnosis and therapy of PCa [ 6 , 7 ]. However, PSMA is even overexpressed in other tumors beyond PCa and in other organs and tissues [ 6 , 7 ].…”

Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence

“…Radioligand therapy with [177Lu]-PSMA-617 improves patients' overall survival by decreasing the risk of death in more than one-third of metastatic castration-resistant PCa patients [20][21][22] who have progressed after conventional treatments. Novel PSMA-targeting immunotherapies, small molecules, and antibody therapies are currently in clinical development, also in earlier stages of PCa, with emerging evidence of antitumor activity [23]. However, patient selection is crucial to avoid a false negative scan, thus optimizing health economic resources [24].…”

Growth, Proliferation and Metastasis of Prostate Cancer Cells Is Blocked by Low-Dose Curcumin in Combination with Light Irradiation

“…Akt serves as a major target to block prostate cancer growth, proliferation, adhesion, and invasion. A phase 2 clinical trial has shown that blocking Akt, compared to second-line chemotherapy [28], is associated with tumor shrinkage and delayed disease progression in the significant subset of patients with metastatic castration-resistant prostate cancer. Randomized trials combining an Akt inhibitor with androgen deprivation (abiraterone, enzalutamide) are currently underway [29].…”